As potential eye drug competitor Lucentis nears market, Eyetech Pharmaceuticals Inc. agreed to merge with OSI Pharmaceuticals Inc., bringing along its approved product Macugen, in a deal worth $935 million - or $20 a share, a 43 percent premium over Eyetech's closing stock price on Friday. (BioWorld Today) Read More